New Observational Studies Confirm the Safety of Renin–Angiotensin–Aldosterone System Blockers in Patients with Covid-19

Editorial: Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19 – New England Journal of Medicine

Study 1: Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 – New England Journal of Medicine

Study 2: Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 – New England Journal of Medicine

Study 3: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 – New England Journal of Medicine

Study 4: Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study – Hypertension

Commentary: Blood Pressure Drugs Don’t Increase Coronavirus Risk, Studies Find – The New York Times

See also: Observational Study: Renin-Angiotensin System Inhibitors are Not Associated with Severity or Mortality in Hospitalized Patients with Coronavirus Disease (2 other studies on the subject)